BIOHealthcare · Medical DevicesThe 3 Wall Street analysts covering Bio-Rad Laboratories, Inc. hold a median 12-month price target of $335 — -11.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 3 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Bio-Rad Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Growth (44): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −11.7% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $370 → $390 |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $300 → $330 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $320 → $370 |
| 5 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $310 → $330 |
| 15 May 2026 | RBC Capital | Reinstates | Outperform | $320 |
| 1 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 7 Apr 2026 | Citigroup | Downgrade | Neutral | — |
| 16 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 30 Oct 2025 | Citigroup | Maintains | Buy | — |
| 30 Oct 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 1 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 1 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 June 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 2 May 2025 | Citigroup | Maintains | Buy | — |
| 2 May 2025 | RBC Capital | Maintains | Outperform | — |
| 2 May 2025 | UBS | Maintains | Buy | — |
| 17 Apr 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 12 Feb 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 Jan 2025 | RBC Capital | Reiterates | Outperform | — |
| 9 Dec 2024 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BIO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Bio-Rad Laboratories, Inc. returned +22.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 15% of US stocks
Cheaper than 30% of US stocks
Cheaper than 56% of US stocks
Cheaper than 13% of US stocks
Higher than 28% of US stocks
Higher than 56% of US stocks
Higher than 66% of US stocks
Higher than 66% of US stocks
Higher than 66% of US stocks
Higher than 50% of US stocks
Higher than 56% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bio-Rad Laboratories, Inc. has a market value of $10.0B and an enterprise value of $9.5B.
Revenue in the twelve months to 30 June 2026: $2.6B. The latest quarter shrank 0.1% year on year.
Net income over the same four quarters: $222.4M, a 8.6% net margin.
Diluted earnings per share, trailing twelve months: $8.25.
Free cash flow in the twelve months to 30 June 2026: $353.1M.
Bio-Rad Laboratories, Inc. spent $132.7M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 47.3×; forward P/E: 38.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Bio-Rad Laboratories, Inc. employs 7,450 people — $348K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bio-Rad Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bio-Rad Laboratories reported Q3 earnings of $2.65 per share, above the Zacks consensus estimate of $2.61. Earnings were $2.26 per share in the year-earlier quarter.
Why it matters — The result gives BIO watchers an update on quarterly earnings relative to analyst expectations and the prior-year period.
Bio-Rad announced financial results for the third quarter ended September 30, 2026. CEO Norman Schwartz said the company returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for Droplet Digital.
Why it matters — The update describes Bio-Rad's reported revenue-growth direction and names the business areas cited as drivers.
Bio-Rad announced that CFO Roop K. Lakkaraju will participate in a fireside chat at the UBS Global Healthcare Conference on November 10, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available through the company’s Investor Relations section.
Why it matters — BIO watchers can follow the CFO’s conference remarks via the webcast or replay.
Ariel Appreciation Fund’s Q3 2026 scorecard says Charles River Laboratories advanced after strong earnings and higher full-year guidance. It also reports exiting NCLH, investing the proceeds in Royal Caribbean Group, and Middleby’s spin-off, planned business exit, and share buybacks.
Why it matters — The excerpt does not mention Bio-Rad Laboratories, so it offers no company-specific information for BIO watchers.
Bio-Rad shares benefited from the announcement of a broad restructuring program intended to streamline operations and enhance profitability.
Why it matters — The restructuring announcement is relevant to BIO watchers because the excerpt identifies it as a factor benefiting the company's shares.
The 3 Wall Street analysts covering Bio-Rad Laboratories, Inc. have a median 12-month price target of $335, with estimates ranging from $280 to $390. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Bio-Rad Laboratories, Inc., 1 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bio-Rad Laboratories, Inc. 92 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Bio-Rad Laboratories, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies -11.7% from the last close, and Ticker Nerd's factor model ranks Bio-Rad Laboratories, Inc. 92 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bio-Rad Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $390 over the next 12 months.
Bio-Rad Laboratories, Inc. returned +22.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates". Bio-Rad Laboratories reported Q3 earnings of $2.65 per share, above the Zacks consensus estimate of $2.61. Earnings were $2.26 per share in the year-earlier quarter.
Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing. Bio-Rad Laboratories Inc. serves two main business segments: Life Science and Clinical Diagnostics. Its Life Science portfolio includes instruments, reagents, consumables, software, and content used to separate, purify, identify, and analyze biological materials such as cells, proteins, and nucleic acids. Its Clinical Diagnostics offerings include test systems, test kits, informatics tools, and quality controls used in areas such as diabetes monitoring, blood typing, infectious disease testing, autoimmune disorders, and genetic analysis. The company’s products are used by universities, hospitals, public health organizations, commercial laboratories, biotechnology firms, pharmaceutical companies, and food and environmental testing customers. Headquartered in Hercules, California, Bio-Rad Laboratories Inc. is recognized as a global supplier of tools that support scientific discovery and diagnostic decision-making.
CEO Mr. Norman D. Schwartz · 7,450 employees · United States · https://www.bio-rad.com
